Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKS03 in Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659Phase 1Recruiting
- Sponsor
- Iksuda Therapeutics
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of LCB73 in B-cell non-Hodgkin lymphoma (5 arms), sponsored by Iksuda Therapeutics. Primary endpoints: Recommended Phase 2 Dose up to 20 months and Objective Response Rate up to 42 months. Started Sep 2023; status: recruiting.
02
Drugs
LCB73
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05365659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365659.